Review of Genomics Data Based on Experience with Mock Submissions
Author Information
Author(s): Leighton John K., Brown Paul, Ellis Amy, Harlow Patricia, Harrouk Wafa, Pine P. Scott, Robison Timothy, Rosario Lilliam, Thompson Karol
Primary Institution: U.S. Food and Drug Administration
Hypothesis
How can pharmacogenomics and toxicogenomics data be effectively reviewed and integrated into drug development?
Conclusion
The review of mock submissions provided insights into the quality and organization of pharmacogenomics data, which can enhance regulatory processes.
Supporting Evidence
- The mock submissions allowed both researchers and regulators to gain experience in reviewing toxicogenomics data.
- The study identified areas needing additional consideration before integrating pharmacogenomics into drug development.
- Quality control metrics were emphasized as essential for evaluating genomics data submissions.
Takeaway
This study looked at how to better understand and review genetic data related to drug safety, helping scientists and regulators work together.
Methodology
The study involved reviewing mock submissions of pharmacogenomics data to assess their content, format, and quality control metrics.
Potential Biases
Potential biases may arise from the voluntary nature of the mock submissions and the lack of standardization in data reporting.
Limitations
The mock submissions were not conducted under Good Laboratory Practice (GLP) regulations, which may affect the reliability of the findings.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website